Lazuriton Nano Biotechnology 10-Q14 Sep 212020 Q3 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2020	Sep. 30, 2021
Cover [Abstract]
Entity Registrant Name	Lazuriton Nano Biotechnology (U.S.A.) Inc.
Entity Central Index Key	0001666178
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	true
Entity Emerging Growth Company	true
Entity Current Reporting Status	No
Document Period End Date	Sep. 30, 2020
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding		100,000,000
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	333-210091
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	37-1786808
Entity Address Address Line 1	341, Sec. 2, Wanshou Road, 10th Floor
Entity Address Address Line 2	Guishan District
Entity Address City Or Town	Taoyuan City
Entity Address Country	CN
Entity Address Postal Zip Code	333
City Area Code	011
Local Phone Number	886-3-329-5585
Security 12b Title	None
Entity Interactive Data Current	No

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 1,348	$ 1,347
Total current assets	1,348	1,347
Total Assets	1,348	1,347
Current Liabilities
Accrued expenses	58,747	36,595
Due to related parties	243,428	233,288
Total current liabilities	302,175	269,883
Total Liabilities	302,175	269,883
Stockholders' Deficit
Common stock, $0.0001 par value; 750,000,000 shares authorized, 100,000,000 shares issued and outstanding	10,000	10,000
Additional paid-in capital	250,000	250,000
Accumulated deficit	(560,827)	(528,536)
Total stockholders' deficit	(300,827)	(268,536)
Total Liabilities and Stockholders' Deficit	$ 1,348	$ 1,347

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Stockholders' deficit
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	100,000,000	100,000,000
Common stock, shares outstanding	100,000,000	100,000,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
Net revenue	$ 0	$ 0	$ 0	$ 0
General and administrative expenses	10,818	17,245	32,292	52,325
Loss from operations	(10,818)	(17,245)	(32,292)	(52,325)
Other income
Interest income	0	0	1	0
Total other income	0	0	1	0
Loss before income taxes	(10,818)	(17,245)	(32,291)	(52,325)
Provision for income taxes	0	0	0	0
Net loss	$ (10,818)	$ (17,245)	$ (32,291)	$ (52,325)
Net loss per share
Basic and diluted	$ 0	$ 0	$ 0	$ 0
Weighted Average Shares Outstanding:
Basic and diluted	100,000,000	100,000,000	100,000,000	100,000,000

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash Flows from Operating Activities
Net loss	$ (32,291)	$ (52,325)
Changes in assets and liabilities:
Decrease in prepaid expense	0	922
Increase in accrued expenses	22,152	2,059
Increase in due to related parties	10,140	49,494
Net cash provided by operating activities	1	150
Net increase in cash and cash equivalents	1	150
Cash and Cash Equivalents
Beginning	1,347	1,197
Ending	1,348	1,347
Cash paid during the year for:
Interest expenses	0	0
Income taxes	$ 0	$ 0

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Dec. 31, 2018		100,000,000
Balance, amount at Dec. 31, 2018	$ (196,761)	$ 10,000	$ 250,000	$ (456,761)
Net loss	(20,607)	$ 0	0	(20,607)
Balance, shares at Mar. 31, 2019		100,000,000
Balance, amount at Mar. 31, 2019	(217,368)	$ 10,000	250,000	(477,368)
Balance, shares at Dec. 31, 2018		100,000,000
Balance, amount at Dec. 31, 2018	(196,761)	$ 10,000	250,000	(456,761)
Net loss	(52,325)
Balance, shares at Sep. 30, 2019		100,000,000
Balance, amount at Sep. 30, 2019	(249,086)	$ 10,000	250,000	(509,086)
Balance, shares at Mar. 31, 2019		100,000,000
Balance, amount at Mar. 31, 2019	(217,368)	$ 10,000	250,000	(477,368)
Net loss	(14,473)	$ 0	0	(14,473)
Balance, shares at Jun. 30, 2019		100,000,000
Balance, amount at Jun. 30, 2019	(231,841)	$ 10,000	250,000	(491,841)
Net loss	(17,245)	$ 0	0	(17,245)
Balance, shares at Sep. 30, 2019		100,000,000
Balance, amount at Sep. 30, 2019	(249,086)	$ 10,000	250,000	(509,086)
Balance, shares at Dec. 31, 2019		100,000,000
Balance, amount at Dec. 31, 2019	(268,536)	$ 10,000	250,000	(528,536)
Net loss	(11,450)	$ 0	0	(11,450)
Balance, shares at Mar. 31, 2020		100,000,000
Balance, amount at Mar. 31, 2020	(279,986)	$ 10,000	250,000	(539,986)
Balance, shares at Dec. 31, 2019		100,000,000
Balance, amount at Dec. 31, 2019	(268,536)	$ 10,000	250,000	(528,536)
Net loss	(32,291)
Balance, shares at Sep. 30, 2020		100,000,000
Balance, amount at Sep. 30, 2020	(300,827)	$ 10,000	250,000	(560,827)
Balance, shares at Mar. 31, 2020		100,000,000
Balance, amount at Mar. 31, 2020	(279,986)	$ 10,000	250,000	(539,986)
Net loss	(10,023)	$ 0	0	(10,023)
Balance, shares at Jun. 30, 2020		100,000,000
Balance, amount at Jun. 30, 2020	(290,009)	$ 10,000	250,000	(550,009)
Net loss	(10,818)	$ 0	0	(10,818)
Balance, shares at Sep. 30, 2020		100,000,000
Balance, amount at Sep. 30, 2020	$ (300,827)	$ 10,000	$ 250,000	$ (560,827)

NATURE OF OPERATIONS AND SUMMAR

NATURE OF OPERATIONS AND SUMMARY OF ACCOUNTING POLICIES	9 Months Ended
NATURE OF OPERATIONS AND SUMMARY OF ACCOUNTING POLICIES	Sep. 30, 2020
NATURE OF OPERATIONS AND SUMMARY OF ACCOUNTING POLICIES
NOTE 1. NATURE OF OPERATIONS AND SUMMARY OF ACCOUNTING POLICIES	NOTE 1. NATURE OF OPERATIONS AND SUMMARY OF ACCOUNTING POLICIES Organization Lazuriton Nano Biotechnology (U.S.A.) Inc., a company in the developmental stage (the “Company”), was incorporated on June 2, 2015 in the State of Nevada. The Company has conducted limited business operations and had no revenues from operations since its inception. The Company’s business plan is to market and distribute Nano fertilizers products. On March 9, 2020, Lazuriton Co., Ltd, a wholly-owned subsidiary was established in the Republic of China, Taiwan. The subsidiary was established for business operations in Taiwan. Going Concern These condensed consolidated financial statements were prepared on the basis of accounting principles applicable to going concern, which assumes the realization of assets and discharge of liabilities in the normal course of business. As shown in the accompanying condensed consolidated financial statements, the Company has incurred net loss $32,291 for the nine months ended September 30, 2020 and net loss of $52,325 for the nine months ended September 30, 2019, and had accumulated deficit of $560,827 and $528,536 as of September 30, 2020 and December 31, 2019, respectively. The Company faces all the risks common to companies at development stage, including capitalization and uncertainty of funding sources, high initial expenditure levels, uncertain revenue streams, and difficulties in managing growth. The Company's losses raise substantial doubt about its ability to continue as a going concern. The Company's financial statements do not reflect any adjustments that might result from the outcome of this uncertainty. The Company is currently addressing its liquidity issue by continually seeking additional funds through private placements of its securities and/or capital contributions and loans by Chih-Yuan Hsiao, the President and a member of the board of directors. The Company believes its current and future plans enable it to continue as a going concern. The Company's ability to achieve these objectives cannot be determined at this time, however. If the Company is unable to obtain additional financing, it may be required to reduce the scope of its business development activities, which could harm its business plans, financial condition and operating results. Additional funding may not be available on favorable terms, if at all. These consolidated financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts which may differ from those in the accompanying consolidated financial statements. Principle of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant inter-company accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the amount of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. However, actual results could differ materially from those results. Foreign Currency Translation and Transactions The reporting and functional currency of the Company is the USD. The functional currency of Lazuriton Co., Ltd, a wholly owned subsidiary of the Company, is the New Taiwanese Dollar (“TWD”). For financial reporting purposes, the financial statements of the Company’s Taiwan subsidiary, which are prepared using the TWD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive income in stockholders’ deficit. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction gain (loss), is included in the accompanying condensed consolidated statements of operations. Cash and Cash Equivalents Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less. Net Income (Loss) Per Share Basic income (loss) per share is computed by dividing net income (loss) by weighted average number of shares of common stock outstanding during each period. Diluted income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. At September 30, 2020 and December 31, 2019, the Company does not have any outstanding common stock equivalents; therefore, a separate computation of diluted loss per share is not presented. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion, or all, of a deferred tax asset will not be realized. The deferred income tax assets were $0 as of both September 30, 2020 and December 31, 2019. The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires that the Company recognizes deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax basis of assets and liabilities by using enacted tax rates expected to apply to taxable income in the periods in which the deferred tax liability or asset is expected to be settled or realized. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when, in the opinion of management, it is more likely than not that some or all of any deferred tax assets will not be realized. Recent Accounting Pronouncements The Company has considered all recent accounting pronouncements issued and their potential effects on its financial statements. The Company's management believes that these recent pronouncements will not have a material effect on the Company's condensed financial statements.

ACCRUED EXPENSES

ACCRUED EXPENSES	9 Months Ended
ACCRUED EXPENSES	Sep. 30, 2020
ACCRUED EXPENSES
NOTE 2. ACCRUED EXPENSES	NOTE 2. ACCRUED EXPENSES Accrued expenses consist of the following: September 30, 2020 December 31, 2019 Accrued professional fees $ 55,329 $ 32,329 Accrued edgar agent service fees 868 3,066 Accrued transfer agent fees 2,550 1,200 Total $ 58,747 $ 36,595

DUE TO RELATED PARTIES

DUE TO RELATED PARTIES	9 Months Ended
DUE TO RELATED PARTIES	Sep. 30, 2020
DUE TO RELATED PARTIES
NOTE 3. DUE TO RELATED PARTIES	NOTE 3. DUE TO RELATED PARTIES The Company has received advances from its officers and shareholders for working capital purposes. As of September 30, 2020 and December 31, 2019, there were $243,428 and $233,288 advances outstanding, respectively. The Company has agreed that the outstanding balances bear 0% interest rate and are due upon demand after 30 days written notice by the officer and shareholder.

INCOME TAXES

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2020
INCOME TAXES
NOTE 4. INCOME TAXES	NOTE 4. INCOME TAXES As of September 30, 2020, the Company had net operating loss carryforwards of approximately $560,827 that may be available to reduce future years’ taxable income. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The provision for federal income tax consists of the following for the nine months ended September 30, 2020 and 2019, respectively: For the Nine Months Ended September 30, 2020 2019 Federal income tax benefit attributable to: Current Operations $ 6,781 $ 10,988 Less: valuation allowance (6,781 ) (10,988 ) Net provision for Federal income taxes $ - $ - The tax effects of temporary differences and carryforwards that give rise to significant portions of deferred tax assets and liabilities consist of the following as of September 30, 2020 and December 31, 2019, respectively: September 30, 2020 December 31, 2019 Deferred tax asset attributable to: Net operating loss carryover $ 117,774 $ 110,993 Less: valuation allowance (117,774 ) (110,993 ) Net deferred tax asset $ - $ - The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below: For the Nine Months Ended September 30, 2020 2019 Statutory federal tax benefit (21 )% (21 )% Change in deferred tax asset valuation allowance 21 % 21 % Provision for income taxes - % - % For the nine months ended September 30, 2020 and 2019, the Company had no unrecognized tax benefits and related interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions.

SUBSEQUENT EVENT

SUBSEQUENT EVENT	9 Months Ended
SUBSEQUENT EVENT	Sep. 30, 2020
SUBSEQUENT EVENT
NOTE 5. SUBSEQUENT EVENT	NOTE 5. SUBSEQUENT EVENT In May 2021, the Company’s wholly owned subsidiary, Lazuriton Co., Ltd., was terminated by the local government due to inactivity. Management has evaluated subsequent events through the date which the financial statements are available to be issued. All subsequent events requiring recognition as of September 30, 2020 have been incorporated into these condensed consolidated financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”

NATURE OF OPERATIONS AND SUMM_2

NATURE OF OPERATIONS AND SUMMARY OF ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2020
NATURE OF OPERATIONS AND SUMMARY OF ACCOUNTING POLICIES
Organization	Lazuriton Nano Biotechnology (U.S.A.) Inc., a company in the developmental stage (the “Company”), was incorporated on June 2, 2015 in the State of Nevada. The Company has conducted limited business operations and had no revenues from operations since its inception. The Company’s business plan is to market and distribute Nano fertilizers products. On March 9, 2020, Lazuriton Co., Ltd, a wholly-owned subsidiary was established in the Republic of China, Taiwan. The subsidiary was established for business operations in Taiwan.
Going Concern	These condensed consolidated financial statements were prepared on the basis of accounting principles applicable to going concern, which assumes the realization of assets and discharge of liabilities in the normal course of business. As shown in the accompanying condensed consolidated financial statements, the Company has incurred net loss $32,291 for the nine months ended September 30, 2020 and net loss of $52,325 for the nine months ended September 30, 2019, and had accumulated deficit of $560,827 and $528,536 as of September 30, 2020 and December 31, 2019, respectively. The Company faces all the risks common to companies at development stage, including capitalization and uncertainty of funding sources, high initial expenditure levels, uncertain revenue streams, and difficulties in managing growth. The Company's losses raise substantial doubt about its ability to continue as a going concern. The Company's financial statements do not reflect any adjustments that might result from the outcome of this uncertainty. The Company is currently addressing its liquidity issue by continually seeking additional funds through private placements of its securities and/or capital contributions and loans by Chih-Yuan Hsiao, the President and a member of the board of directors. The Company believes its current and future plans enable it to continue as a going concern. The Company's ability to achieve these objectives cannot be determined at this time, however. If the Company is unable to obtain additional financing, it may be required to reduce the scope of its business development activities, which could harm its business plans, financial condition and operating results. Additional funding may not be available on favorable terms, if at all. These consolidated financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts which may differ from those in the accompanying consolidated financial statements.
Principle of Consolidation	The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant inter-company accounts and transactions have been eliminated in consolidation.
Use of Estimates	The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the amount of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. However, actual results could differ materially from those results.
Foreign Currency Translation and Transactions	The reporting and functional currency of the Company is the USD. The functional currency of Lazuriton Co., Ltd, a wholly owned subsidiary of the Company, is the New Taiwanese Dollar (“TWD”). For financial reporting purposes, the financial statements of the Company’s Taiwan subsidiary, which are prepared using the TWD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive income in stockholders’ deficit. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction gain (loss), is included in the accompanying condensed consolidated statements of operations.
Cash and Cash Equivalents	Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.
Net Income (Loss) Per Share	Basic income (loss) per share is computed by dividing net income (loss) by weighted average number of shares of common stock outstanding during each period. Diluted income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. At September 30, 2020 and December 31, 2019, the Company does not have any outstanding common stock equivalents; therefore, a separate computation of diluted loss per share is not presented.
Income Taxes	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion, or all, of a deferred tax asset will not be realized. The deferred income tax assets were $0 as of both September 30, 2020 and December 31, 2019. The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires that the Company recognizes deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax basis of assets and liabilities by using enacted tax rates expected to apply to taxable income in the periods in which the deferred tax liability or asset is expected to be settled or realized. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when, in the opinion of management, it is more likely than not that some or all of any deferred tax assets will not be realized.
Recent Accounting Pronouncements	The Company has considered all recent accounting pronouncements issued and their potential effects on its financial statements. The Company's management believes that these recent pronouncements will not have a material effect on the Company's condensed financial statements.

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	9 Months Ended
ACCRUED EXPENSES (Tables)	Sep. 30, 2020
ACCRUED EXPENSES
Schedule of accrued expenses	September 30, 2020 December 31, 2019 Accrued professional fees $ 55,329 $ 32,329 Accrued edgar agent service fees 868 3,066 Accrued transfer agent fees 2,550 1,200 Total $ 58,747 $ 36,595

INCOME TAXES (Tables)

INCOME TAXES (Tables)	9 Months Ended
INCOME TAXES (Tables)	Sep. 30, 2020
INCOME TAXES
Schedule of provision for federal income tax	For the Nine Months Ended September 30, 2020 2019 Federal income tax benefit attributable to: Current Operations $ 6,781 $ 10,988 Less: valuation allowance (6,781 ) (10,988 ) Net provision for Federal income taxes $ - $ -
Schedule of tax effects of temporary differences and carryforwards	September 30, 2020 December 31, 2019 Deferred tax asset attributable to: Net operating loss carryover $ 117,774 $ 110,993 Less: valuation allowance (117,774 ) (110,993 ) Net deferred tax asset $ - $ -
Schedule of effective rate reflected in provision for income taxes on loss before taxes	For the Nine Months Ended September 30, 2020 2019 Statutory federal tax benefit (21 )% (21 )% Change in deferred tax asset valuation allowance 21 % 21 % Provision for income taxes - % - %

NATURE OF OPERATIONS AND SUMM_3

NATURE OF OPERATIONS AND SUMMARY OF ACCOUNTING POLICIES (Detail Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
NATURE OF OPERATIONS AND SUMMARY OF ACCOUNTING POLICIES
Net loss	$ (10,818)	$ (10,023)	$ (11,450)	$ (17,245)	$ (14,473)	$ (20,607)	$ (32,291)	$ (52,325)
Accumulated deficit	(560,827)						(560,827)		$ (528,536)
Deferred income tax assets	$ 0						$ 0		$ 0

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
ACCRUED EXPENSES
Accrued professional fees	$ 55,329	$ 32,329
Accrued edgar agent service fees	868	3,066
Accrued transfer agent fees	2,550	1,200
Total	$ 58,747	$ 36,595

DUE TO RELATED PARTIES (Detail

DUE TO RELATED PARTIES (Detail Narrative) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
DUE TO RELATED PARTIES
Due to related parties	$ 243,428	$ 233,288
Percentage of interest rates on advances outstanding	0.00%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	3 Months Ended		9 Months Ended
INCOME TAXES (Details) - USD ($)	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Federal income tax benefit attributable to:
Current operations			$ 6,781	$ 10,988
Less: Valuation allownce			(6,781)	(10,988)
Net provision for Federal income taxes	$ 0	$ 0	$ 0	$ 0

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Deferred tax asset attributable to:
Net operating loss carryover	$ 117,774	$ 110,993
Less: valuation allowance	(117,774)	(110,993)
Net deferred tax asset	$ 0	$ 0

INCOME TAXES (Details 2)

INCOME TAXES (Details 2)	9 Months Ended
INCOME TAXES (Details 2)	Sep. 30, 2020	Sep. 30, 2019
INCOME TAXES
Statutory federal tax benefit	(21.00%)	(21.00%)
Change in deferred tax asset valuation allowance	21.00%	21.00%
Provision for income taxes	0.00%	0.00%

INCOME TAXES (Detail Narrative)

INCOME TAXES (Detail Narrative)	Sep. 30, 2020USD ($)
INCOME TAXES
Net operating loss carry forwards	$ 560,827